c-Met comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The first pictorial evidence for cheesemaking was found on a frieze at the Temple of the Great Goddess of Life, Ninhursag, in Mesopotamia in the Fertile Crescent – a region which covers modern day Iraq – and is 5,000 years old. The frieze depicts priests engaged in the production of cow dairy and perhaps creating curd mixture somewhat similar to cottage cheese. A fictional story on the origin of cheese was taken from Homer's Odyssey, in which the poet describes how the Cyclops, Polyphemus, made cheese by storing milk in animal stomachs. The enzyme rennin from animals stomachs induces a coagulation process separating the curds from the whey. As Rome expanded its empire, it spread the knowledge of cheese, discovering many new forms. The Romans introduced cheesemaking to England. Over centuries, European farmers made farmhouse cheeses using fermented-soured milk, then separated the whey from curds as an early form of cottage cheese.
==== Celanese synthesis ==== An alternative industrial synthesis developed at Celanese involves firstly direct acylation of phenol with acetic anhydride in the presence of hydrogen fluoride to give a methyl ketone, then the conversion of the ketone with hydroxylamine to a ketoxime, and finally the acid-catalysed Beckmann rearrangement of the oxime to the amide in the para-acetylaminophenol product.
Flory correctly identified that the chain dimension in polymer melts would have the size computed for a chain in ideal solution if excluded volume interactions were neutralized by experimenting at the theta point. Among his accomplishments are an original method for computing the probable size of a polymer in good solution, the Flory-Huggins Solution Theory, the extension of polymer physics concepts to the field of liquid crystals, and the derivation of the Flory exponent, which helps characterize the movement of polymers in solution.
Saddam's foreign minister Tariq Aziz later told PBS Frontline in 1996 that the Iraqi leadership was under "no illusion" about America's likely response to the Iraqi invasion: "She [Glaspie] didn't tell us anything strange. She didn't tell us in the sense that we concluded that the Americans will not retaliate. That was nonsense you see. It was nonsense to think that the Americans would not attack us." Then in a second 2000 interview with the same television program, Aziz said:There were no mixed signals. We should not forget that the whole period before August 2 witnessed a negative American policy towards Iraq. So it would be quite foolish to think that, if we go to Kuwait, then America would like that. Because the American tendency ... was to untie Iraq. So how could we imagine that such a step was going to be appreciated by the Americans? It looks foolish, you see, this is fiction. About the meeting with April Glaspie—it was a routine meeting...She didn't say anything extraordinary beyond what any professional diplomat would say without previous instructions from his government...what she said were routine, classical comments on what the president was asking her to convey to President Bush. He wanted her to carry a message to George Bush—not to receive a message through her from Washington.
Sources: en.wikipedia.org
While BIA Separations was the first to commercially market polymeric monoliths, Merck KGaA was the first company to market silica monoliths. In 1996, Tanaka and coworkers at the Kyoto Institute of Technology published extensive work on silica monolith technologies. Merck was later issued a license from Kyoto Institute of Technology to develop and produce the silica monoliths. Promptly thereafter, in 2001, Merck introduced its Chromolith line of monolithic HPLC columns at analytical instrumentation trade show PittCon. Initially, says Karin Cabrera, senior scientist at Merck, the high flow rate was the selling point for the Chromolith line. Based on customer feedback, though, Merck soon learned that the columns were more stable and longer-lived than particle-packed columns. The columns were the recipients of various new product awards. Difficulties in production of the silica monoliths and tight patent protection have precluded attempts by other companies at developing a similar product. It has been noted that there are more patents concerning how to encapsulate the silica rod than there are on the manufacture of the silica itself. Historically, Merck has been known for its superior chemical products, and, in liquid chromatography, for the purity and reliability of its particulate silica. Merck is not known for its LC columns. Five years after the introduction of its Chromolith line, Merck made a very strategic marketing decision.
In petroleum engineering, in situ techniques involve the application of heat or solvents to extract heavy crude oil or bitumen from reservoirs located beneath the Earth's surface. Several in situ methods exist, but those that utilize heat, particularly steam, have proven to be the most effective for oil sands extraction. The most widely used in situ technique is steam-assisted gravity drainage (SAGD). This method employs two horizontal wells: the upper well injects steam to heat the bitumen, reducing its viscosity, while the lower well collects the mobilized oil for extraction. SAGD has gained prominence in the Canadian province of Alberta, due to its efficiency in recovering bitumen from deep reservoirs. Approximately 80% of Alberta's oil sands deposits are located at depths that render open-pit mining impractical, making in situ techniques such as SAGD the primary method of extraction.
The Mustang was initially developed for the RAF, which was its first user. As the first Mustangs were built to British requirements, these aircraft used factory numbers and were not P-51s; the order comprised 320 NA-73s, followed by 300 NA-83s, all of which were designated Mustang Mark I by the RAF. The first RAF Mustangs supplied under Lend-Lease were 93 Mk Ia designated as P-51s by the USAAF, followed by 50 P-51As used as Mustang Mk IIs. Aircraft supplied to Britain under Lend-Lease were required for accounting purposes to be on the USAAC's books before they could be supplied to Britain, but the British Aircraft Purchasing Commission signed its first contract for the North American NA-73 on 24 April 1940, before Lend-Lease was in effect. After the arrival of the initial aircraft in the UK in October 1941, the first squadron of Mustang Mk Is entered service in January 1942, the first being No. 26 Squadron RAF. Due to poor high-altitude performance, the Mustangs were used by Army Co-operation Command, rather than Fighter Command, and were used for tactical reconnaissance and ground-attack duties. On 10 May 1942, Mustangs first flew over France, near Berck-sur-Mer. On 27 July 1942, 16 RAF Mustangs undertook their first long-range reconnaissance mission over Germany. During the amphibious Dieppe Raid on the French coast (19 August 1942), four British and Canadian Mustang squadrons, including 26 Squadron, saw action covering the assault on the ground. By 1943–1944, British Mustangs were used extensively to seek out V-1 flying bomb sites.
Its inhabitants—referred to as "Wellies"—wear white "Happy Face" masks, which were created to forcefully mold the wearer's cheekbones into a smile, resulting in the wearer permanently smiling. Joy is freely dispensed in pill form and is also laced into the city's water supply. To encourage the drug's consumption, the media is tightly controlled and centers on "Uncle" Jack Worthing, a friendly presenter whose voice and image widely broadcasts government propaganda over the city's televisions and radios. Some Wellies developed immunity to Joy—partly due to ingesting bad batches of the drug—and subsequently became depressed or insane from remembering the Very Bad Thing; these people were then driven out of Wellington Wells and came to be known as "Wastrels". Others who voluntarily refuse their Joy are known as "Downers" and seen as a threat; if caught, Downers are either force-fed Joy, are taken to a Joy Doctor to get a potentially lethal liquid injection of Joy, or are outright killed on the spot. As a result, Wellington Wells has become a dystopian police state on the verge of collapse.
==== Clinical evidence ==== The amount typically used in clinical trials is 1200–2400 mg/day of red yeast rice containing approximately 10 mg total monacolins, of which half are monacolin K. A meta-analysis reported LDL-cholesterol lowered by 1.02 mmol/L (39.4 mg/dL) compared to placebo. The incidence of reported adverse effects ranged from 0% to 5% and was not different from controls. A second meta-analysis incorporating more recent clinical trials also reported significant lowering of total cholesterol and LDL-cholesterol. Within the first review, the largest and longest duration trial was conducted in China. Close to 5,000 post-heart attack patients were enrolled for an average of 4.5 years to receive either a placebo or a RYR product named xuezhikang (Chinese: 血脂康; pinyin: xuè zhī kāng). The test product was an ethanol extract of red yeast rice, with a monacolin K content of 11.6 mg/day. Key results: in the treated group, risk of subsequent heart attacks was reduced by 45%, cardio deaths by 31%, and all-cause deaths by 33%. These heart attack and cardiovascular death outcomes appear to be better than what has been reported for prescription statin drugs. A 2008 review pointed out that the cardioprotective effects of statins in Japanese populations occur at lower doses than are needed in Western populations, and theorized that the low amount of monacolins found in the xuezhikang product might have been more effectively athero-protective than expected in the Chinese population for the same reason.
Sources: en.wikipedia.org
adenosine diphosphate (ADP) A nucleoside diphosphate consisting of adenosine attached to two consecutive phosphate groups via high-energy ester bonds. ADP can be phosphorylated to produce ATP and thus is a precursor for its synthesis; it can also be dephosphorylated into AMP.
Bernstein interpreted this as indicating that Engels was moving towards accepting parliamentary reformist and gradualist stances, but he ignored that Engels' stances were tactical as a response to the particular circumstances at that time and that Engels was still committed to revolutionary socialism. Engels was deeply distressed when he discovered that his introduction to a new edition of The Class Struggles in France had been edited by Bernstein and Karl Kautsky in a manner which left the impression that he had become a proponent of a peaceful road to socialism. On 1 April 1895, four months before his death, Engels responded to Kautsky:
=== Phases of growth === Potato growth can be divided into five phases. During the first phase, sprouts emerge from the seed potatoes and root growth begins. During the second, photosynthesis begins as the plant develops leaves and branches above-ground and stolons develop from lower leaf axils on the below-ground stem. In the third phase the tips of the stolons swell, forming new tubers, and the shoots continue to grow, with flowers typically developing soon after. Tuber bulking occurs during the fourth phase, when the plant begins investing the majority of its resources in its newly formed tubers. At this phase, several factors are critical to a good yield: optimal soil moisture and temperature, soil nutrient availability and balance, and resistance to pest attacks. The fifth phase is the maturation of the tubers: the leaves and stems senesce and the tuber skins harden. New tubers may start growing at the surface of the soil. Since exposure to light leads to an undesirable greening of the skins and the development of solanine as a protection from the sun's rays, growers cover surface tubers. Commercial growers cover them by piling additional soil around the base of the plant as it grows (called "hilling" up, or in British English "earthing up"). An alternative method, used by home gardeners and smaller-scale growers, involves covering the growing area with mulches such as straw or plastic sheets. At farm scale, potatoes require a well-drained neutral or mildly acidic soil (pH 6 or 7) such as a sandy loam.
=== Distribution in a plant === Not all cells in a multicellular plant contain chloroplasts. All green parts of a plant contain chloroplasts as the color comes from the chlorophyll. The plant cells which contain chloroplasts are usually parenchyma cells, though chloroplasts can also be found in collenchyma tissue. A plant cell which contains chloroplasts is known as a chlorenchyma cell. A typical chlorenchyma cell of a land plant contains about 10 to 100 chloroplasts. In some plants such as cacti, chloroplasts are found in the stems, though in most plants, chloroplasts are concentrated in the leaves. One square millimeter of leaf tissue can contain half a million chloroplasts. Within a leaf, chloroplasts are mainly found in the mesophyll layers of a leaf, and the guard cells of stomata. Palisade mesophyll cells can contain 30–70 chloroplasts per cell, while stomatal guard cells contain only around 8–15 per cell, as well as much less chlorophyll. Chloroplasts can also be found in the bundle sheath cells of a leaf, especially in C4 plants, which carry out the Calvin cycle in their bundle sheath cells. They are often absent from the epidermis of a leaf.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.